Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2026
Pharma News, 2026
Corcept Shares Tumble After FDA Letter Reveals Warnings Before Drug Rejection
Corcept shares fell 16% after a corrected FDA letter revealed warnings against submitting relacorilant for Cushing's due to efficacy and safety issues.
Pharma M&A Set to Boom in 2026: $240 Billion Deal Value in 2025
Pharma M&A deal value rose 81% to $240 billion in 2025. Big Pharma acquisitions and China biotech innovation drive 2026 boom expectations.
FDA Accepts Otsuka’s Centanafadine Application for ADHD Treatment
FDA accepts Otsuka's NDA for centanafadine, a novel NDSRI for ADHD. Priority review granted with PDUFA date of July 24, 2026.
Biogen's Autoimmune Candidate Litifilimab Gets FDA Breakthrough Status
FDA grants Breakthrough Therapy designation to Biogen's litifilimab for cutaneous lupus erythematosus based on phase II LILAC study results.
AstraZeneca Pledges $15bn for China R&D and Manufacturing Expansion
AstraZeneca invests $15bn in China R&D and manufacturing to boost cell therapy and oncology pipeline, aligning with Healthy China 2030 strategy.
Eli Lilly Outlays $1.12bn for Hearing Loss Gene Therapy Partnership
Lilly and Seamless Therapeutics sign $1.12bn deal for recombinase-based gene therapies for hearing loss and DNA editing.
Solvonis Expands SVN-015 into Depression Following Positive Preclinical Data
Solvonis expands SVN-015 SDRI into depression after positive preclinical data showing antidepressant activity comparable to fluoxetine.
Boehringer Pens €1.05B Deal for Simcere's Preclinical IBD Bispecific SIM0709
Boehringer Ingelheim signs €1.05B deal for Simcere’s SIM0709, a bispecific antibody targeting TL1A and IL-23p19 for inflammatory bowel disease.
China Clears Huahui Health’s Libevitug as First Drug for Chronic Hepatitis D
Huahui Health wins NMPA approval for libevitug, China's first drug for chronic hepatitis D, plugging a major gap in treatment options.
Trial of Myeloma Therapy KLN-1010 Gets FDA Green Light to Expand to US
Phase 1 inMMyCAR trial for myeloma therapy KLN-1010 expands to US. Kelonia Therapeutics testing genetic therapy in relapsed or refractory patients.
Aclaris ATI-2138 Shows Rapid Hair Regrowth in Alopecia Areata Model
Aclaris’ ITK/JAK3 inhibitor ATI-2138 showed rapid hair regrowth in a murine alopecia model, outperforming ritlecitinib.
MSD Ends Takeover Talks with Revolution Medicines Over Price
MSD ends talks to acquire Revolution Medicines after failing to agree on price. Deal was valued at $28bn-$32bn. Revolution market cap is $23bn.
6
7
8
9
10
11
12
13
14
